MedTrace Logo

Tumor Registry Pancreatic Cancer

NCT02089269 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2325

Last updated 2025-01-30

No results posted yet for this study

Summary

The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Conditions

  • Pancreas Cancer

Sponsors & Collaborators

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Susanna Hegewisch-Becker, Prof. MD · Outpatient Clinic, Hamburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2022-04-14
Completion
2024-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02089269 on ClinicalTrials.gov